Craig Rundbaken, DO
Pulmonary Disease · Sun City West, AZNPI 1720072903
Payments from drug & device makers
Across 264 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$664
- Boehringer Ingelheim$625
- GSK$587
- Insmed, Inc.$440
- Electromed, Inc.$389
- Pulmonx Corporation$274
- plus $2K from 28 others
What the payments were for
- Consulting fees$170%
- Food & beverage$5,30797%
- Education$1272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $664 |
| Boehringer Ingelheim | 25 | $625 |
| GSK | 41 | $587 |
| Insmed, Inc. | 28 | $440 |
| Electromed, Inc. | 29 | $389 |
| Pulmonx Corporation | 7 | $274 |
| Philips North America LLC | 11 | $269 |
| Harmony Biosciences LLC | 11 | $254 |
| Verona Pharma, Inc. | 8 | $233 |
| Baxter Healthcare | 10 | $224 |
| Mayne Pharma Commercial LLC | 18 | $186 |
| 3b Medical, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $117 |
| Itamar Medical Inc | 3 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| Grifols USA, LLC | 3 | $81 |
| Jazz Pharmaceuticals Inc. | 3 | $79 |
| United Therapeutics Corporation | 4 | $78 |
| Viatris Specialty LLC | 3 | $70 |
| Genentech USA, Inc. | 3 | $70 |
| Inspire Medical Systems, Inc. | 2 | $66 |
| ZOLL Respicardia, Inc. | 2 | $56 |
| Amgen | 3 | $53 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $44 |
| Lilly USA, LLC | 3 | $42 |
| Sanofi | 2 | $41 |
| Noctrix Health, Inc. | 1 | $38 |
| Novartis | 1 | $33 |
| Mylan Specialty L.p. | 1 | $29 |
| Inogen, Inc. | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| CSL Behring | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,451 in reported general payments places this provider in the 60th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 779 | $794,324 |
| OfevNintedanib Esylate | 27 | $355,670 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $189,114 |
| Breo ElliptaFluticasone/Vilanterol | 256 | $145,793 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 139 | $131,341 |
| Spiriva RespimatTiotropium Bromide | 159 | $129,537 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 392 | $72,254 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 105 | $71,124 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $68,693 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 56 | $41,888 |
| SymbicortBudesonide/Formoterol Fumarate | 110 | $40,556 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 995 | $32,520 |
| Wixela InhubFluticasone Propion/Salmeterol | 197 | $25,843 |
| Spiriva HandihalerTiotropium Bromide | 19 | $25,105 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $18,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $587 | $1,038,1211,213 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $625 | $595,789308 claims |
| Grifols USA, LLCProlastin C | $81 | $189,11413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $664 | $188,631262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Sun City West
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
- George ParidesMesa$913K
- Richard SueGilbert$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.